Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

UK Biopharma and life after Brexit

Paul Ranson, of global law firm Morgan Lewis’ London Life Science’s Practice, examines how the UK Biopharma must now adapt to a changing landscape.

Read More »

FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson and Genmab

Johnson & Johnson has indicated that its acute myeloid leukemia (AML) drug, JNJ-63709178, has been put on clinical hold because of serious side effects.

Read More »

Astellas, Vical herpes vaccine fails mid-stage study

Japan’s Astellas Pharma Inc. and San Diego-based Vical Inc. said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

Read More »

Global fund raises $12.9 billion to fight AIDS, TB and malaria

A global fund has raised over $12.9 billion from international donors as part of a campaign aimed at effectively eradicating AIDS, malaria and tuberculosis by 2030, conference organizers said.

Read More »

Novartis says MS drug cut risk of disability advance in study

Novartis’ investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said, citing a new analysis of a late-stage trial.

Read More »

J&J Pays $4.325 Billion for Abbott’s Eye Surgery Biz

Johnson & Johnson announced it will acquire Abbott Medical Optics for more than $4 billion. The deal is expected to close in the first quarter of 2017.

Read More »

U.S. Justice Dept to push prosecutors on opioid crisis – USA Today

The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported.

Read More »

Brain cancer now deadliest for U.S. children: study

Brain cancer is now the deadliest form of childhood cancer in the United States, surpassing leukemia as treatment advances have allowed doctors to cure many blood-related cancers, the Centers for Disease Control and Prevention said.

Read More »

EMA panel recommends nod for Pfizer’s breast cancer drug

U.S. drugmaker Pfizer Inc.’s breast cancer drug Ibrance should be given marketing approval, an advisory committee at the European Medicines Agency recommended.

Read More »

Forxiga combo beats use of drug alone

AstraZeneca said combining its Forxiga diabetes drug with Bydureon was more effective at controlling blood sugar levels than treatment with either drug on its own.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom